ArticleThe Journal of experimental medicine1997
The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.
Article in The Journal of experimental medicine, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 426 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
426 citing papers in PubMed, 1,389 citations in OpenAlex.
- Circulating hematopoietic stem/progenitor cell subsets contribute to human hematopoietic homeostasis.Blood · 2024Trial
- Effect of high-dose plerixafor on CD34Haematologica · 2017Trial
- Bone marrow skeletal stem/progenitor cell defects in dyskeratosis congenita and telomere biology disorders.Blood · 2015Trial
- Integrating gene-microbiome interactions and single-cell transcriptomics reveals therapeutic strategies for aortic aneurysm.iScience · 2026Article
- Longitudinal localization of leukaemic stem cells between the metaphysis and central marrow governs their behaviour.Nature cell biology · 2026Article
- Circulating pro-angiogenic cells are preserved despite myocardial angiogenic signal deficits in HFpEF model.Scientific reports · 2026Article
- Stromal-Derived Factor-1 (SDF-1/CXCL12) and Skin Wound Healing Research at the Intersection Between Regenerative Biology and Medicine.International journal of molecular sciences · 2026Review
- Impact of aging on CD146Frontiers in bioengineering and biotechnology · 2026Article
- CXCR4/CXCR7 gene-silencing suppresses ovarian cancer cell proliferation and tumour growth through modulation of the CXCL12-CXCR4/CXCR7 chemokine axis and activation of MAPK signalling pathway.Archives of medical science : AMS · 2026Article
- HSC engraftment is enhanced by combining mobilization with anti-C-Kit and Anti-CD47-based conditioning in hematopoietic transplant.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Quantification of intrinsic regulatory factors refines human hematopoietic progenitor definitions and reveals early erythroid lineage priming.Cell reports · 2025Article
- DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications.Current issues in molecular biology · 2025Review
- Article
- Article
- Emerging insights into epigenetics and hematopoietic stem cell trafficking in age-related hematological malignancies.Stem cell research & therapy · 2024Review
- Bone marrow mesenchymal stem cells overexpressing stromal cell- derived factor 1 aid in bone formation in osteoporotic mice.BMC musculoskeletal disorders · 2024Article
- Navigating uncharted waters: assessing the impact of the COVID-19 pandemic on hematopoietic stem cell transplantation: challenges and innovations.Annals of medicine and surgery (2012) · 2024Review
- Challenges and innovations in hematopoietic stem cell transplantation: exploring bone marrow niches and new model systems.BMB reports · 2024Review
- Injectable Self-Oxygenating Cardio-Protective and Tissue Adhesive Silk-Based Hydrogel for Alleviating Ischemia After Mi Injury.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Donor and recipient hematopoietic stem and progenitor cells mobilization in liver transplantation patients.Stem cell research & therapy · 2024Article
366 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Hematopoietic progenitor cells migrate in vitro and in vivo towards a gradient of the chemotactic factor stromal cell-derived factor-1 (SDF-1) produced by stromal cells. This is the first chemoattractant reported for human CD34+ progenitor cells. Concentrations of SDF-1 that elicit chemotaxis also induce a transient elevation of cytoplasmic calcium in CD34+ cells. SDF-1-induced chemotaxis is inhibited by pertussis toxin, suggesting that its signaling in CD34+ cells is mediated by seven transmembrane receptors coupled to Gi proteins. CD34+ cells migrating to SDF-1 include cells with a more primitive (CD34+/CD38- or CD34+/DR-) phenotype as well as CD34+ cells phenotypically committed to the erythroid, lymphoid and myeloid lineages, including functional BFU-E, CFU-GM, and CFU-MIX progenitors. Chemotaxis of CD34+ cells in response to SDF-1 is increased by IL-3 in vitro and is lower in CD34+ progenitors from peripheral blood than in CD34+ progenitors from bone marrow, suggesting that an altered response to SDF-1 may be associated with CD34 progenitor mobilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.